Literature DB >> 2544546

A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium.

M Miyagiwa1, T Ichida, T Tokiwa, J Sato, H Sasaki.   

Abstract

A human cholangiocellular carcinoma cell line, HuCC-T1, was established in vitro from the malignant cells of ascites of a 56-yr-old patient. Histologic findings of the primary liver tumor revealed a moderately differentiated adenocarcinoma. Tumor cells from the ascites have been cultured with RPMI 1640 medium containing 0.2% lactalbumin hydrolysate and the cultured cells grew as monolayers with a population doubling time of 74 h during exponential growth at Passage 25. They had an epithelial-like morphology and were positive for mucine staining. Ultrastructural studies revealed the presence of microvilli on the cell surface and poorly developed organelles in the cytoplasm. The HuCC-T1 cell was tumorigenic in nude mice. The number of chromosomes in HuCC-T1 ranged from 61 to 80. These human cholangiocellular carcinoma cells in serum-free medium secreted several tumor markers, including carbohydrate antigen 19/9, carbohydrate antigen 125, carcinoembryonic antigen, and tissue polypeptide antigen. The carbohydrate antigen 19/9 secretion level of HuCC-T1 cells cultured in RPMI 1640 medium with 1% fetal bovine serum was sixfold higher than that with 0.2% lactalbumin hydrolysate. These findings suggest that HuCC-T1 will provide useful information to clarify the mechanism of tumor marker secretion and tumor cell growth in the human cholangiocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2544546     DOI: 10.1007/BF02623562

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol        ISSN: 0883-8364


  20 in total

1.  Antigenicity of pooled human malignant and normal tissues by cyto-immunological technique; presence of an insoluble, heat-labile tumor antigen.

Authors:  B BJORKLUND; V BJORKLUND
Journal:  Int Arch Allergy Appl Immunol       Date:  1957

2.  Production of immunoreactive calcitonin and some other tumor markers by established human carcinoma cell lines.

Authors:  S Ichiki; M Kuroki; A Matsunaga; M Kuroki; Y Matsuoka
Journal:  Jpn J Cancer Res       Date:  1986-03

3.  In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain.

Authors:  T R Chen
Journal:  Exp Cell Res       Date:  1977-02       Impact factor: 3.905

4.  Establishment and characterization of a human combined hepatocholangiocarcinoma cell line and its heterologous transplantation in nude mice.

Authors:  T Murakami; H Yano; M Maruiwa; S Sugihara; M Kojiro
Journal:  Hepatology       Date:  1987 May-Jun       Impact factor: 17.425

5.  Establishment and characterization of the human cholangiocarcinoma cell line HChol-Y1 in a serum-free, chemically defined medium.

Authors:  N Yamaguchi; H Morioka; H Ohkura; S Hirohashi; K Kawai
Journal:  J Natl Cancer Inst       Date:  1985-07       Impact factor: 13.506

6.  Biliary adenocarcinoma. Characterisation of three new human tumor cell lines.

Authors:  A Knuth; H Gabbert; W Dippold; O Klein; W Sachsse; D Bitter-Suermann; W Prellwitz; K H Meyer zum Büschenfelde
Journal:  J Hepatol       Date:  1985       Impact factor: 25.083

7.  Pathological aspects of cholangiocarcinoma.

Authors:  K Weinbren; S S Mutum
Journal:  J Pathol       Date:  1983-02       Impact factor: 7.996

8.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

Authors:  R C Bast; T L Klug; E St John; E Jenison; J M Niloff; H Lazarus; R S Berkowitz; T Leavitt; C T Griffiths; L Parker; V R Zurawski; R C Knapp
Journal:  N Engl J Med       Date:  1983-10-13       Impact factor: 91.245

9.  Gastrointestinal cancer-associated antigen in immunoperoxidase assay.

Authors:  B F Atkinson; C S Ernst; M Herlyn; Z Steplewski; H F Sears; H Koprowski
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

10.  Tumorigenicity in athymic mice of the human colon carcinoma cell line SW1116 expressing the tumor-associated antigenic determinant CA 19-9.

Authors:  T L Klug; S Salzman; A Quinn; G A Melincoff; D D Sedmak; R R Tubbs; V R Zurawski
Journal:  Cancer Res       Date:  1984-11       Impact factor: 12.701

View more
  53 in total

1.  Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion.

Authors:  Sharon DeMorrow; Paolo Onori; Julie Venter; Pietro Invernizzi; Gabriel Frampton; Mellanie White; Antonio Franchitto; Shelley Kopriva; Francesca Bernuzzi; Heather Francis; Monique Coufal; Shannon Glaser; Giammarco Fava; Fanyin Meng; Domenico Alvaro; Guido Carpino; Eugenio Gaudio; Gianfranco Alpini
Journal:  Am J Physiol Cell Physiol       Date:  2011-01-26       Impact factor: 4.249

2.  miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation.

Authors:  Laurent Ehrlich; Chad Hall; Julie Venter; David Dostal; Francesca Bernuzzi; Pietro Invernizzi; Fanyin Meng; Jerome P Trzeciakowski; Tianhao Zhou; Holly Standeford; Gianfranco Alpini; Terry C Lairmore; Shannon Glaser
Journal:  Am J Pathol       Date:  2017-01-11       Impact factor: 4.307

3.  Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism.

Authors:  Gabriel Frampton; Pietro Invernizzi; Francesca Bernuzzi; Hae Yong Pae; Matthew Quinn; Darijana Horvat; Cheryl Galindo; Li Huang; Matthew McMillin; Brandon Cooper; Lorenza Rimassa; Sharon DeMorrow
Journal:  Gut       Date:  2011-11-07       Impact factor: 23.059

4.  MicroRNA (miR)-433 and miR-22 dysregulations induce histone-deacetylase-6 overexpression and ciliary loss in cholangiocarcinoma.

Authors:  Adrian P Mansini; Maria J Lorenzo Pisarello; Kristen M Thelen; Maetzin Cruz-Reyes; Estanislao Peixoto; Sujeong Jin; Brynn N Howard; Christy E Trussoni; Gabriella B Gajdos; Nicholas F LaRusso; Maria J Perugorria; Jesus M Banales; Sergio A Gradilone
Journal:  Hepatology       Date:  2018-05-21       Impact factor: 17.425

5.  Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells.

Authors:  S Imai; J Nishikawa; K Takada
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

6.  Characterization of a novel rat cholangiocarcinoma cell culture model-CGCCA.

Authors:  Chun-Nan Yeh; Kun-Ju Lin; Tsung-Wen Chen; Ren-Ching Wu; Lee-Cheng Tsao; Ying-Tzu Chen; Wen-Hui Weng; Miin-Fu Chen
Journal:  World J Gastroenterol       Date:  2011-06-28       Impact factor: 5.742

7.  miR-34a-dependent overexpression of Per1 decreases cholangiocarcinoma growth.

Authors:  Yuyan Han; Fanyin Meng; Julie Venter; Nan Wu; Ying Wan; Holly Standeford; Heather Francis; Cynthia Meininger; John Greene; Jerome P Trzeciakowski; Laurent Ehrlich; Shannon Glaser; Gianfranco Alpini
Journal:  J Hepatol       Date:  2016-02-24       Impact factor: 25.083

8.  Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria.

Authors:  Chetan Bettegowda; Long H Dang; Ross Abrams; David L Huso; Larry Dillehay; Ian Cheong; Nishant Agrawal; Scott Borzillary; J Michael McCaffery; E Latice Watson; Kuo-Shyan Lin; Fred Bunz; Kwamena Baidoo; Martin G Pomper; Kenneth W Kinzler; Bert Vogelstein; Shibin Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

9.  Caffeic acid phenethyl ester decreases cholangiocarcinoma growth by inhibition of NF-kappaB and induction of apoptosis.

Authors:  Paolo Onori; Sharon DeMorrow; Eugenio Gaudio; Antonio Franchitto; Romina Mancinelli; Julie Venter; Shelley Kopriva; Yoshiyuki Ueno; Domenico Alvaro; Jennifer Savage; Gianfranco Alpini; Heather Francis
Journal:  Int J Cancer       Date:  2009-08-01       Impact factor: 7.396

10.  Non-canonical Hedgehog signaling contributes to chemotaxis in cholangiocarcinoma.

Authors:  Nataliya Razumilava; Sergio A Gradilone; Rory L Smoot; Joachim C Mertens; Steven F Bronk; Alphonse E Sirica; Gregory J Gores
Journal:  J Hepatol       Date:  2013-11-14       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.